|
86 Companies |
|
137 Products |
|
137 Products |
|
85 Mechanisms of Action |
|
4 Trials |
|
2019 News |
|
| «12...1819202122232425262728...3940» |
- | paliperidone extended release / Generic mfg.
New P4 trial: Early Prediction of Clinical Response in Patients With Schizophrenia Treated by Paliperidone ER (clinicaltrials.gov) - Feb 27, 2014
P4, N=41, Completed, Sponsor: Taipei City Hospital
- EVP6308 / Forum Pharmaceuticals
Trial initiation date: Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Stable Treatment With up to 2 Atypical Antipsychotics (clinicaltrials.gov) - Feb 26, 2014
P1, N=40, Not yet recruiting, Sponsor: FORUM Pharmaceuticals Inc
Initiation date: Feb 2014 --> Sep 2014
- New P1 trial: RECOVERY: RCT of Methotrexate Added to Treatment As Usual in Schizophrenia (clinicaltrials.gov) - Feb 26, 2014
P1, N=100, Recruiting, Sponsor: Pakistan Institute of Learning and Living
- Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment open: Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia (clinicaltrials.gov) - Feb 26, 2014
P4, N=50, Recruiting, Sponsor: New York State Psychiatric Institute
Initiation date: Feb 2014 --> Sep 2014 Not yet recruiting --> Recruiting
- ||||||| Rexulti (brexpiprazole) / Lundbeck, Otsuka
Trial completion: Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia (clinicaltrials.gov) - Feb 26, 2014
P3, N=636, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||||| Rexulti (brexpiprazole) / Lundbeck, Otsuka
Trial completion: BEACON: Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia (clinicaltrials.gov) - Feb 26, 2014
P3, N=674, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| asenapine / Generic mfg.
New P2/3 trial: Bioequivalence Fasting Study in Patients (clinicaltrials.gov) - Feb 25, 2014
P2/3, N=48, Active, not recruiting, Sponsor: Amneal Pharmaceuticals, LLC
- Enrollment closed: Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation (clinicaltrials.gov) - Feb 25, 2014
P2, N=60, Active, not recruiting, Sponsor: University of Pittsburgh
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion: Cognitive Remediation Therapy and Schizophrenia (clinicaltrials.gov) - Feb 23, 2014
P=N/A, N=77, Completed, Sponsor: H
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| Korlym (mifepristone) / Corcept Therap
Trial completion: A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression (clinicaltrials.gov) - Feb 22, 2014
P3, N=257, Completed, Sponsor: Corcept Therapeutics
Active, not recruiting --> Completed Recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study (clinicaltrials.gov) - Feb 22, 2014
P2, N=16, Completed, Sponsor: University of Pittsburgh
Recruiting --> Completed No longer recruiting --> Completed
- ||||||| Korlym (mifepristone) / Corcept Therap
Trial completion: An International Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression (clinicaltrials.gov) - Feb 22, 2014
P3, N=104, Completed, Sponsor: Corcept Therapeutics
No longer recruiting --> Completed No longer recruiting --> Completed
- ||||||| Korlym (mifepristone) / Corcept Therap
Trial completion: A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression (clinicaltrials.gov) - Feb 22, 2014
P3, N=443, Completed, Sponsor: Corcept Therapeutics
No longer recruiting --> Completed Recruiting --> Completed
- |||| Buronil (melperone) / Lundbeck
Trial completion: Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease (clinicaltrials.gov) - Feb 22, 2014
P2, N=90, Completed, Sponsor: Lundbeck LLC
Recruiting --> Completed Active, not recruiting --> Completed
- ||||||| olanzapine / Generic mfg.
Trial completion: Olanzapine Treated Adolescents With Schizophrenia or Bipolar I Disorder (clinicaltrials.gov) - Feb 22, 2014
P3, N=100, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Recruiting --> Completed
- risperidone / Generic mfg., olanzapine / Generic mfg.
Trial completion: The Effects of Risperidone and Olanzapine on Thinking (clinicaltrials.gov) - Feb 22, 2014
P4, N=0, Completed, Sponsor: Department of Veterans Affairs
Recruiting --> Completed No longer recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Generalization of Training in Schizophrenia (clinicaltrials.gov) - Feb 22, 2014
P=N/A, N=0, Completed, Sponsor: Department of Veterans Affairs
No longer recruiting --> Completed No longer recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Effect of Transcranial Magnetic Stimulation on Memory (clinicaltrials.gov) - Feb 22, 2014
P=N/A, N=80, Completed, Sponsor: National Institute of Mental Health (NIMH)
No longer recruiting --> Completed Recruiting --> Completed
- |||| aripiprazole / Generic mfg., olanzapine / Generic mfg.
Trial completion: Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia (clinicaltrials.gov) - Feb 22, 2014
P4, N=600, Completed, Sponsor: Eli Lilly and Company
Recruiting --> Completed Recruiting --> Completed
- ||||||| aripiprazole / Generic mfg.
Trial completion: APEX 241: Aripiprazole Open-Label, Safety and Tolerability Study (clinicaltrials.gov) - Feb 22, 2014
P3, N=325, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting --> Completed No longer recruiting --> Completed
- ||||||| aripiprazole / Generic mfg.
Trial completion: APEX 239: Aripiprazole in Adolescents With Schizophrenia (clinicaltrials.gov) - Feb 22, 2014
P3, N=302, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
No longer recruiting --> Completed No longer recruiting --> Completed
- |||| olanzapine / Generic mfg.
Trial completion: Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder (clinicaltrials.gov) - Feb 22, 2014
P4, N=600, Completed, Sponsor: Eli Lilly and Company
No longer recruiting --> Completed No longer recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Psychiatric Problems in Children and Adolescents Infected With HIV at Birth (clinicaltrials.gov) - Feb 22, 2014
P=N/A, N=800, Completed, Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
No longer recruiting --> Completed Active, not recruiting --> Completed
- |||| NN1213 / Novo Nordisk
Trial completion: Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment in Schizophrenia Patients (clinicaltrials.gov) - Feb 22, 2014
P2, N=138, Completed, Sponsor: Forest Laboratories
Active, not recruiting --> Completed Recruiting --> Completed
- ||||||| aripiprazole / Generic mfg., olanzapine / Generic mfg.
Trial completion: Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder (clinicaltrials.gov) - Feb 22, 2014
P3, N=300, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting --> Completed No longer recruiting --> Completed
- ||||||| quetiapine / Generic mfg.
Trial completion: ANCHOR 112: Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Adolescent Patients With Schizophrenia (clinicaltrials.gov) - Feb 22, 2014
P3, N=249, Completed, Sponsor: AstraZeneca
No longer recruiting --> Completed Recruiting --> Completed
- |||| olanzapine / Generic mfg., quetiapine / Generic mfg.
Trial completion: Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder (clinicaltrials.gov) - Feb 22, 2014
P4, N=340, Completed, Sponsor: Eli Lilly and Company
Recruiting --> Completed No longer recruiting --> Completed
- ||||||| Zyprexa Relprevv (olanzapine pamoate long-acting injection) / Eli Lilly
Trial completion: Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia (clinicaltrials.gov) - Feb 22, 2014
P3, N=1205, Completed, Sponsor: Eli Lilly and Company
No longer recruiting --> Completed Recruiting --> Completed
- ||||||| Zyprexa Relprevv (olanzapine pamoate long-acting injection) / Eli Lilly
Trial completion: Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia (clinicaltrials.gov) - Feb 22, 2014
P3, N=402, Completed, Sponsor: Eli Lilly and Company
Recruiting --> Completed No longer recruiting --> Completed
- ||||||| Zyprexa Relprevv (olanzapine pamoate long-acting injection) / Eli Lilly
Trial completion: Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder (clinicaltrials.gov) - Feb 22, 2014
P3, N=931, Completed, Sponsor: Eli Lilly and Company
No longer recruiting --> Completed Active, not recruiting --> Completed
- |||| aripiprazole / Generic mfg., olanzapine / Generic mfg.
Trial completion: Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia (clinicaltrials.gov) - Feb 22, 2014
P4, N=560, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed No longer recruiting --> Completed
- ||||||| NN1213 / Novo Nordisk
Trial completion: Efficacy & Safety of Quetiapine Fumarate (SEROQUEL) & Placebo in the Treatment of Acutely Ill Patients With Schizophrenia (clinicaltrials.gov) - Feb 22, 2014
P3, N=535, Completed, Sponsor: AstraZeneca
No longer recruiting --> Completed Recruiting --> Completed
- |||| aripiprazole / Generic mfg.
Trial completion: Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia (clinicaltrials.gov) - Feb 22, 2014
P4, N=370, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting --> Completed No longer recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Rehabilitative Training for Older People With Schizophrenia (clinicaltrials.gov) - Feb 22, 2014
P2, N=240, Completed, Sponsor: University of California, San Diego
No longer recruiting --> Completed No longer recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Treatment Response to Rehabilitation in Patients With Schizophrenia (clinicaltrials.gov) - Feb 22, 2014
P=N/A, N=46, Completed, Sponsor: Hartford Hospital
No longer recruiting --> Completed Recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: STOP-PD: Study of Pharmacotherapy of Psychotic Depression (clinicaltrials.gov) - Feb 22, 2014
P3, N=259, Completed, Sponsor: Weill Medical College of Cornell University
Recruiting --> Completed Recruiting --> Completed
- ||||||| olanzapine / Generic mfg.
Trial completion: Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia (clinicaltrials.gov) - Feb 22, 2014
P3, N=107, Completed, Sponsor: Eli Lilly and Company
Recruiting --> Completed No longer recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Treating Drug-Resistant Childhood Schizophrenia (clinicaltrials.gov) - Feb 22, 2014
P4, N=41, Completed, Sponsor: North Shore Long Island Jewish Health System
No longer recruiting --> Completed Recruiting --> Completed
- | citalopram / Generic mfg.
Trial completion: Antidepressant Treatment in Older Adults With Schizophrenia (clinicaltrials.gov) - Feb 22, 2014
P=N/A, N=212, Completed, Sponsor: Veterans Medical Research Foundation
Recruiting --> Completed No longer recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Transcranial Magnetic Stimulation (TMS) Treatment for Patients With Persistent Auditory Hallucinations (clinicaltrials.gov) - Feb 22, 2014
P=N/A, N=50, Completed, Sponsor: Yale University
No longer recruiting --> Completed No longer recruiting --> Completed
- aripiprazole / Generic mfg.
Trial completion: Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders (clinicaltrials.gov) - Feb 22, 2014
P2/3, N=0, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
No longer recruiting --> Completed No longer recruiting --> Completed
- risperidone / Generic mfg., olanzapine / Generic mfg., quetiapine / Generic mfg.
Trial completion: CAFE Comparison of Atypicals in First Episode of Psychosis (clinicaltrials.gov) - Feb 22, 2014
P3, N=0, Completed, Sponsor: AstraZeneca
No longer recruiting --> Completed No longer recruiting --> Completed
- ||| lenrispodun (ITI-214) - Intra / Cellular Therapies
Enrollment open: Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia (clinicaltrials.gov) - Feb 22, 2014
P1, N=64, Recruiting, Sponsor: Takeda
No longer recruiting --> Completed Not yet recruiting --> Recruiting
- Trial initiation date: Transcranial Current Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia (clinicaltrials.gov) - Feb 20, 2014
P=N/A, N=25, Recruiting, Sponsor: University of North Carolina, Chapel Hill
Not yet recruiting --> Recruiting Initiation date: Oct 2013 --> Jan 2014
- Enrollment open: Transcranial Current Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia (clinicaltrials.gov) - Feb 20, 2014
P=N/A, N=25, Recruiting, Sponsor: University of North Carolina, Chapel Hill
Initiation date: Oct 2013 --> Jan 2014 Not yet recruiting --> Recruiting
- | olanzapine / Generic mfg., clozapine / Generic mfg.
Trial completion: Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders (clinicaltrials.gov) - Feb 19, 2014
P4, N=25, Completed, Sponsor: National Institute of Mental Health (NIMH)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Preventive Measures for Childhood-Onset Obsessive-Compulsive Disorder and Tic Disorders (PANDAS Subgroup) (clinicaltrials.gov) - Feb 19, 2014
P2, N=90, Completed, Sponsor: National Institute of Mental Health (NIMH)
Active, not recruiting --> Completed No longer recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Neuropsychiatric Evaluation of Healthy Volunteers and Adults With Schizophrenia (clinicaltrials.gov) - Feb 19, 2014
P=N/A, N=810, Completed, Sponsor: National Institute of Mental Health (NIMH)
No longer recruiting --> Completed Recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: FamCent: Self-Management Therapy for Youth With Schizophrenia (clinicaltrials.gov) - Feb 19, 2014
P3, N=40, Completed, Sponsor: National Institute of Mental Health (NIMH)
Recruiting --> Completed No longer recruiting --> Completed
- bitopertin (DISC-1459) / Disc Medicine
Biomarker, Enrollment change: A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Participants With Schizophrenia and Schizoaffective Disorder (clinicaltrials.gov) - Feb 19, 2014
P1, N=31, Completed, Sponsor: Hoffmann-La Roche
No longer recruiting --> Completed N=40 --> 31